Clinical Trial Update: A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study of Tolododekin Alfa (ANK-101) in combination with an anti-PD-1/PD-L1 antibody in adults with advanced non-small cell lung cancer is currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anti-PD-1/PD-L1 antibody (investigational)
• Tolododekin Alfa (ANK-101) (Tolododekin Alfa)

Snippet

Sponsor: Ankyra Therapeutics, Inc | Conditions: Non Small Cell Lung Cancer | Phase 1 | Status: RECRUITING